Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Polish Journal of Microbiology
Volume 71 (2022): Issue 2 (June 2022)
Open Access
Oral Microbiota, a Potential Determinant for the Treatment Efficacy of Gastric
Helicobacter pylori
Eradication in Humans
Huixia Chen
Huixia Chen
,
Hui Xie
Hui Xie
,
Dong Shao
Dong Shao
,
Liju Chen
Liju Chen
,
Siyu Chen
Siyu Chen
,
Lin Wang
Lin Wang
and
Xiao Han
Xiao Han
| May 31, 2022
Polish Journal of Microbiology
Volume 71 (2022): Issue 2 (June 2022)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Related Materials
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Original Paper
Published Online:
May 31, 2022
Page range:
227 - 239
Received:
Jan 05, 2022
Accepted:
Mar 22, 2022
DOI:
https://doi.org/10.33073/pjm-2022-020
Keywords
eradication
,
therapeutic effects
,
oral microbiota
,
sequencing
© 2022 Huixia Chen et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig. 1
Sample collection and qualification of 16S rRNA sequencing.A) A schematic diagram illustrating the sample collection process; B) rarefaction curve analysis; C) specaccum curve analyses; D) rank abundance analysis; n = 7 for the SE group, n = 9 for the FE group; FE – failure eradication, SE – successful eradication, HP – Helicobacter pylori.
Fig. 2
α and β Diversity analyses.A) Observed species, Chao1 richness, ACE index, Shannon index, Simpson index, and J index were calculated for α diversity of the oral microbiota.
Fig. 2
α and β Diversity analyses.B) PCoA analysis for β diversity of the oral microbiota; SE – patients with successful eradication therapy, FE – patients with failed eradication therapy.
Fig. 3
Component analysis of community structure.A) Relative abundances of the ten most abundant bacterial phyla in the FE and SE groups; B) relative abundances of the indicated individuals’ ten most abundant bacterial phyla; C) t-test analysis comparing oral microbiota composition between the FE and SE groups.
Fig. 3
Component analysis of community structure.D) cladogram generated from LEfSe analysis.
Fig. 3
Component analysis of community structure.E) LDA scores of significantly altered taxa presented in panel D; n = 7 for the SE group, n = 9 for the FE group; SE – patients with successful eradication therapy, FE – patients with failed eradication therapy.
Fig. 4
Correlation analysis of microbial environmental factors.A) RDA analysis comparing OTUs between the FE and SE groups.
Fig. 4
Correlation analysis of microbial environmental factors.E) KEGG analysis diagram; n = 7 for the SE group, n = 9 for the FE group; SE – patients with successful eradication therapy, FE – patients with failed eradication therapy.
Fig. 4
Correlation analysis of microbial environmental factors.B) heat map analysis based on RDA analysis showing the abundance of 14 OTUs influenced by Helicobacter pylori infection.
Fig. 4
Correlation analysis of microbial environmental factors.C) correlations of the abundances of 14 OTUs with DOB values, ages, sex, and treatment status in patients from either FE or SE groups;*p < 0.05, **p < 0.01; PICRUSt2 function prediction of changed OTUs; D) PCA analysis.
Fig. 5
Venn analysis revealing differently affected and overlapping OTUs between the FE and SE groups; n = 7 for the SE group, n = 9 for the FE group; SE – patients with successful eradication therapy, FE – patients with failed eradication therapy.
Preview